Lineage Cell Therapeutics LCTX
NYSE LCTX
$1.08 -0.02 (-1.82%)
As of: Sep 4, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Operating Margin (QoQ) (2010 - 2026)

Analysis

Lineage Cell Therapeutics (LCTX) Operating Margin (QoQ) (2010 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Lineage Cell Therapeutics 270.71 Mn 213.99 Mn 1.07 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -39,453.00
Mar 31, 2026 -34,108.00
Dec 31, 2025 376.00
Sep 30, 2025 61,252.00
Jun 30, 2025 -28,228.00
Mar 31, 2025 -25,492.00
Dec 31, 2024 -7,656.00
Sep 30, 2024 31,508.00
Jun 30, 2024 4,460.00
Mar 31, 2024 -15,659.00
Dec 31, 2023 23,343.00
Sep 30, 2023 -38,234.00
Jun 30, 2023 12,259.00
Mar 31, 2023 6,831.00
Dec 31, 2022 -17,153.00
Sep 30, 2022 -8,216.00
Jun 30, 2022 2,914.00
Mar 31, 2022 -6,565.00
Dec 31, 2021 24,498.00
Sep 30, 2021 108,136.00